ArticleFrontiers in oncology2026
Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is the CALLY Index the Best Tool for Predicting Survival in Patients with Primary Soft Tissue Sarcomas?Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trabectedin is a standard treatment for advanced soft tissue sarcomas (STS) after anthracycline failure. However, reliable prognostic markers remain limited. This study aims to evaluate the prognostic significance of inflammatory indices and the modified Glasgow Prognostic Score (mGPS) in STS patients treated with trabectedin. Methods: We retrospectively analyzed 60 patients with advanced soft tissue sarcoma treated with trabectedin between 2015 and 2024 across multiple tertiary oncology centers. Baseline laboratory parameters obtained within two days prior to treatment initiation were used to calculate neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), pan-immune-inflammation value (PIV), inflammatory burden index (IBI), prognostic nutritional index (PNI), and modified Glasgow Prognostic Score (mGPS). Associations with overall survival were evaluated using Cox proportional hazards regression. Skewed continuous variables were log-transformed prior to analysis. To reduce the risk of overfitting, a limited number of clinically relevant variables were included in the multivariate model, while potential collinearity among inflammatory indices was considered. Results: A total of 37 patients (61.7%) were female, with a median age of 54.5 years (range: 35-77). Leiomyosarcoma was the predominant histological subtype, observed in 55% of cases. Trabectedin was administered at a median of the third-line setting (range: 2nd to 5th line). The objective response rate (ORR) was 24%, while the disease control rate (DCR) was 56%. The median follow-up duration was 10.2 months (range: 1-50.7). Median progression-free survival (PFS) was 4.9 months, and median overall survival (OS) was 11.7 months. Patients with mGPS 0 had significantly longer OS than those with mGPS 1 or 2 (median OS: 20.5 vs. 10.1 and 10.9 months; p = 0.006). In multivariate analysis, higher mGPS (1-2 vs 0) remained independently associated with worse OS (HR 3.9; 95% CI 1.5-10.0; p = 0.004). Conclusion: In this multicenter real-world cohort, mGPS was identified as an independent prognostic factor for overall survival in patients with advanced soft tissue sarcoma treated with trabectedin. These findings support its potential utility for prognostic stratification, warranting further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.